-
公开(公告)号：AU2006242431A1
公开(公告)日：2006-11-09
申请号：AU2006242431
申请日：2006-04-28
Applicant: UCB PHARMA SA , AMGEN INC
Inventor： SHEN WENYAN , PASZTY CHRISTOPHER , HENRY ALISTAIR JAMES , GRAHAM KEVIN , POPPLEWELL ANDY , HOFFMANN KELLY SUE , WINTERS AARON GEORGE , LAWSON ALASTAIR , LU HSIENG SEN , ROBINSON MARTYN KIM , LATHAM JOHN , WINKLER DAVID
Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin-binding agents, such as antibodies capable of binding to sclerostin, are provided.
-
公开(公告)号：NO348331B1
公开(公告)日：2024-11-25
申请号：NO20230084
申请日：2023-01-31
Applicant: AMGEN INC , UCB PHARMA SA
Inventor： LATHAM JOHN , PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LAWSON ALASTAIR , LU HSIENG SEN , POPPLEWELL ANDY , SHEN WENYAN , WINKLER DAVID , WINTERS AARON GEORGE
IPC: C07K16/18 , A61K39/395 , A61P19/08 , A61P19/10 , C07K14/51
-
公开(公告)号：ES2901698T3
公开(公告)日：2022-03-23
申请号：ES10014360
申请日：2006-04-28
Applicant: UCB PHARMA SA , AMGEN INC
Inventor： LU HSIENG SEN , PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LATHAM JOHN , LAWSON ALASTAIR , WINKLER DAVID , WINTERS AARON GEORGE
IPC: C07K16/22 , A61K39/00 , A61P15/12 , A61P19/00 , A61P19/08 , A61P19/10 , A61P43/00 , C07K14/51 , C12N15/63
Abstract: Un anticuerpo monoclonal que bloquea de forma cruzada la unión del anticuerpo Ab-C o Ab-D con esclerostina o se bloquea de forma cruzada su unión con esclerostina por el anticuerpo Ab-C o Ab-D, donde el anticuerpo Ab-C tiene cadenas ligeras de SEQ ID NO: 15 y cadenas pesadas de SEQ ID NO: 19 y Ab-D tiene cadenas ligeras de SEQ ID NO: 7 y cadenas pesadas de SEQ ID NO: 11, donde el bloqueo cruzado se determina por el ensayo de Biacore, donde el anticuerpo de bloqueo cruzado se une a esclerostina en el ensayo de Biacore de forma que durante el ensayo y en presencia de un segundo anticuerpo la unión registrada es de entre el 80 % y el 0,1 % de la unión teórica máxima de los dos anticuerpos en combinación, o donde el bloqueo cruzado se determina por ELISA, donde el anticuerpo en fase de solución provoca una reducción de entre el 60 % y el 100 % de la cantidad de esclerostina con la que se une el anticuerpo que recubre la placa de ELISA en comparación con la cantidad de esclerostina con la que se une el anticuerpo de recubrimiento en ausencia del anticuerpo en fase de solución, y donde el anticuerpo aumenta al menos uno de formación de hueso, densidad mineral ósea, contenido mineral óseo, masa ósea, calidad ósea y fuerza ósea en un mamífero.
-
公开(公告)号：DK3670528T3
公开(公告)日：2021-12-06
申请号：DK19211623
申请日：2006-04-28
Applicant: UCB PHARMA SA , AMGEN INC
-
公开(公告)号：PH12015501848A1
公开(公告)日：2020-07-06
申请号：PH12015501848
申请日：2015-08-20
Applicant: AMGEN INC , UCB PHARMA SA
Inventor： POPPLEWELL ANDY , PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LATHAM JOHN , LAWSON ALASTAIR , LU HSIENG SEN , SHEN WENYAN , WINKLER DAVID , WINTERS AARON GEORGE
Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
-
Patent Agency Ranking
公开(公告)号：CA2681530C
公开(公告)日：2017-03-28
申请号：CA2681530
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C12N15/13 , A61K39/395 , C07K16/28 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody.
-
公开(公告)号：CA2607197C
公开(公告)日：2016-12-13
申请号：CA2607197
申请日：2006-04-28
Applicant: AMGEN INC , UCB PHARMA SA
Inventor： PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LATHAM JOHN , LAWSON ALASTAIR , LU HSIENG SEN , POPPLEWELL ANDY , SHEN WENYAN , WINKLER DAVID , WINTERS AARON GEORGE
IPC: C07K16/22 , A61K39/395 , C07K14/475 , C07K14/51 , C07K16/18 , C12N15/13 , C12P21/08
Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
-
公开(公告)号：AU2013285488A1
公开(公告)日：2015-02-19
申请号：AU2013285488
申请日：2013-07-03
Applicant: UCB PHARMA SA
Inventor： ROBINSON MARTYN KIM
IPC: C07K16/22 , A61K39/395
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
-
公开(公告)号：BRPI0809042A2
公开(公告)日：2014-09-16
申请号：BRPI0809042
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：CR20140081A
公开(公告)日：2014-03-25
申请号：CR20140081
申请日：2014-02-19
Applicant: AMGEN INC , UCB PHARMA SA
Inventor： PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LATHAM JOHN , LAWSON ALASTAIR , LU HSIENG SEN , POPPLEWELL ANDY , SHEN WENYAN , WINKLER DAVID , WINTERS AARON
IPC: C07K14/51
Abstract: Se brindan composiciones y métodos relacionados a epitopos de la proteína esclerostinay los agentes de fijación de esclerostina, tales como anticuerpos capaces de fijarse a la esclerostina.
-
-
-
-
-
-
-
-
-
Search Results
66
records
(took 0.023 seconds)
